Ignite Creation Date:
2024-05-06 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03519542
Status:
COMPLETED
Last Update Posted:
2019-09-18
First Post:
2014-10-29
Brief Title:
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma
Sponsor:
Spanish Oncology Genito-Urinary Group
Organization:
Spanish Oncology Genito-Urinary Group
Study Overview
Official Title:
Muticentric and Prospective Epidemiological Study to Identify Prognosis and Predictive Biomarkers of Response to Angiogenic Drugs Approved in First Line of Treatment for Advanced or Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SOGANG
Brief Summary:
Multicentric and prospective epidemiological study NON INTERVETIONAL to identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in metstatic renal cell carcinoma
Molecular determinations will be developed ay CIMA and CNIO
Molecular determinations will be developed ay CIMA and CNIO
Detailed Description:
In coming years new TKIs for the treatment of mRCC are expected to be available Identificaction of novel biomarkers is required to select those patients who would most benefit from a particular therapeutic strategy
C-Met is a tyrosine kinase receptor involved in cellular growth and vascular develoment also identify as a proto-oncogene
Chemiokines an increase in pro-angiogenic chemokines such as IL-6 IL-8 has been also suggested as a tumor dependent possible mechanism influencing invasion and metastasis after anti-VEGF therapy
PBRM1 BAF 180 mutation Second major involved gene in clear cell RCC with truncating mutations in 41 92227 of cases Mutations appear to inactive a protein that plays role in remodeling the structure of genetic materialPBRM1 mutations could be partially involved in about 40 of clear cell RCC PBRM1 may affect the processes of cell divsion in renal cells and could consequently be another target for new drugs
C-Met is a tyrosine kinase receptor involved in cellular growth and vascular develoment also identify as a proto-oncogene
Chemiokines an increase in pro-angiogenic chemokines such as IL-6 IL-8 has been also suggested as a tumor dependent possible mechanism influencing invasion and metastasis after anti-VEGF therapy
PBRM1 BAF 180 mutation Second major involved gene in clear cell RCC with truncating mutations in 41 92227 of cases Mutations appear to inactive a protein that plays role in remodeling the structure of genetic materialPBRM1 mutations could be partially involved in about 40 of clear cell RCC PBRM1 may affect the processes of cell divsion in renal cells and could consequently be another target for new drugs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None